Exploring Two Dividend Powerhouses Worth Holding Long-term

Understanding the Benefits of Long-term Stockholding

Investing wisely in stocks, particularly with a long-term vision, can be one of the most rewarding financial strategies. Following the footsteps of seasoned investors like Warren Buffett can help guide your investment choices. Long-term stockholding can lead to numerous tax advantages, and reinvesting dividends allows the power of compounding to amplify your returns. Research indicates that a significant portion of the S&P 500's gains since 1960 stem from reinvested dividends and the compounding effect.

Two Prominent Dividend Stocks for Your Portfolio

AbbVie: A Strong Performer

AbbVie has cemented its position as a formidable player in the pharmaceutical industry thanks, in part, to its blockbuster drug, Humira, which treats various autoimmune disorders. Despite Humira losing exclusivity recently, AbbVie has shown resilience. In its latest quarter, AbbVie recorded a year-over-year revenue increase of 4.3%, reaching $14.5 billion.

The company's portfolio of immunology products, particularly Skyrizi and Rinvoq, are proving essential in offsetting the decline in Humira sales. AbbVie's leadership anticipates that these two therapies might collectively exceed $27 billion in sales by 2027, suggesting a bright future ahead. Notably, Humira previously peaked at annual sales of $21.2 billion.

AbbVie isn't resting on its laurels; the company is actively pursuing innovation. It filed for FDA approval for a new drug, telisotuzumab vedotin, aimed at treating non-small cell lung cancer. Moreover, promising phase 3 trial results for tavapadon, a potential Parkinson's disease treatment, position AbbVie for continued growth with new therapeutics on the horizon.

Novartis: The Innovator

Novartis stands out as another major entity in the healthcare sector. Its diversified selection of approved medications significantly contributes to its revenue trajectory. For example, the heart failure treatment Entresto saw sales grow by an impressive 25% to $1.9 billion compared to the same quarter last year. The cancer treatment Kisqali also performed remarkably well, with sales of $717 million, reflecting a 45% increase compared to the previous year.

In the last quarter, 14 of Novartis' top 20 brands recorded year-over-year sales growth, resulting in a 9% total revenue increase to $12.5 billion. This performance reflects the strength of Novartis’ product pipeline and its commitment to innovative medicine.

Focusing on future growth, Novartis recently introduced Fabhalta, which targets proteinuria in patients suffering from IgA nephropathy—a kidney condition. Novartis emphasizes that many patients with IgA nephropathy currently lack effective treatment options. Additionally, a new potential therapy, atrasentan, is under development for the same condition.

After spinning off its generics and biosimilars unit, Novartis is now entirely committed to innovative pharmaceutical developments, boasting a pipeline filled with over 100 programs.

Why These Stocks Are Noteworthy

Both AbbVie and Novartis offer compelling dividend propositions for income-driven investors. AbbVie, recognized as a Dividend King, has maintained 52 consecutive years of dividend increases and currently yields about 3.2%. Novartis is also impressive with a 27-year increasing streak and a current yield of 3.3%. With robust dividends and promising growth potential, these two companies exemplify strong options for investors seeking to establish a solid portfolio for the long term.

Frequently Asked Questions

What makes AbbVie a compelling investment?

AbbVie is recognized for its strong revenue growth driven by new drug developments and its successful product line, particularly in the immunology space.

How has Novartis performed recently?

Recently, Novartis experienced significant revenue growth, with a notable increase in sales of critical products like Entresto and Kisqali.

What are dividends, and why are they important?

Dividends are payments made by a company to its shareholders, often seen as a reward. They can provide a steady income stream, making dividend-paying stocks attractive for long-term investments.

Why should I consider long-term stockholding?

Long-term stockholding allows for capital appreciation, potential for compound returns through reinvested dividends, and various tax advantages.

Which tickers should I research further?

Investors looking to explore promising dividend stocks might want to investigate AbbVie (NYSE: ABBV) and Novartis (NYSE: NVS) further.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.